Redefining Roles: From Medical Practice to Biotech Ventures : 32

The Emerging Biotech Leader
The Emerging Biotech Leader
Redefining Roles: From Medical Practice to Biotech Ventures : 32

In this episode of the Emerging Biotech Leader podcast, hosts Kim Kushner and Ramin Farhood interview Keith Gottesdiener, President and CEO of Prime Medicine. They discuss Keith's unconventional career path, which spans roles as a physician, research scientist, drug development leader at Merck for over 16 years, and entrepreneurial biotech CEO at Rhythm Pharmaceuticals before joining Prime Medicine.

A key theme is Keith's approach of purposefully taking on new challenges outside his comfort zone at pivotal career junctures to expand his skills and experiences. He began as a practicing physician and research scientist, spending around eight years treating patients and conducting academic research. However, he found the slow pace of academia too limiting for his impatient, entrepreneurial mindset and what he wanted to achieve in life.

Keith talks about the transition to his first CEO role at Rhythm, where he had to quickly learn areas like fundraising, board management, and shaping the company culture despite his extensive pharma background. He emphasizes the criticality of building the right team with a collaborative, agile mindset suited for the biotech environment. Keith shares his philosophy that "People are really what makes a biotech have the opportunity to form a culture that will allow biotech to succeed" and his methods for evaluating and recruiting talent aligned with the company's vision.

He contrasts the experiences of biotech company building versus his big pharma tenure at Merck, mentioning the need for flexibility and navigating funding challenges amidst the current constrained investment cycle while trying to rapidly scale Prime Medicine. The conversation also touches on Prime Medicine's new therapeutic approach via its proprietary technology, as well as Keith's perspectives on leadership and entrepreneurial mindsets.

Overall, the episode provides insights into the multifaceted skillset required to lead ambitious, transformative scientific endeavors as a biotech entrepreneur.

Are you leading a biotech and would like to share your experience with our podcast audience? We'd love to hear from you! Please reach out to us.

More Episodes Like This


Daring to Fail Forward: The Mindset Catalyzing Healthcare Breakthroughs – Christian Howell : 34

This episode features an interview with Christian Howell, Chief Commercial Officer at Cognito Therapeutics, a biotech company pioneering a neurotechnology approach to treat Alzheimer's disease. Christian draws on his diverse background spanning the mili...

Avoiding Common Pitfalls in the Biotech Development Process – Dr. Thomas Lönngren : 33

Episode Overview: In this podcast interview, Ramin Farhood hosts Dr. Thomas Lönngren, an expert in drug regulation, approval, and market access. Thomas has an impressive career spanning over three decades, including a transformative tenure as the exe...

Balancing Current Needs and Long-Term Goals in Biotech : 31

Building evolving biotech organizations requires balancing short-term demands with long-term objectives. Leveraging leaders as cross-functional connectors and prioritizing self-awareness and humility are paramount for driving organizational success.

Growing Early Biotech Startups Through Connection – Dan Bloomfield : 30

Gaining cross-functional exposure and leveraging expertise across the organization is invaluable. Building optimal teams through full-time hires and consultants, and cultivating an entrepreneurial mindset drives success in leadership roles.

Lessons In Biotechs with Bold Missions : 29

Large-scale studies and longitudinal data play key roles in demonstrating impact on outcomes, costs, and clinical utility. These research efforts, when meeting established standards, can support significant advancements in patient care approaches.

Lessons In Clinical Trials With The Unlikely Entrepreneur – Jim Min : 28

Research-informed strategies may influence clinical practices toward prevention. Cardiology advancements incorporate digital tools and imaging technologies, potentially contributing to earlier detection and improved outcomes.


You don't have to go it alone! Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs.

This field is for validation purposes and should be left unchanged.